NCT03343626 - Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Participants | Biotech Hunter

Enrollment

271

Participants

Timeline

Start Date

November 13, 2017

Primary Completion Date

December 28, 2018

Study Completion Date

November 24, 2020

Conditions

Virus, ZikaZika Virus DiseaseFlavivirus InfectionsHealthy Participants

Interventions

DRUG

Placebo

Placebo (normal saline (0.9% NaCl) IM injection.

BIOLOGICAL

PIZV

Purified inactivated Zika virus vaccine with aluminum hydroxide adjuvant IM injection.

Trial Locations (9)

Regional Clinical Research Inc., Endwell

Rochester Clinical Research, Rochester

Clinical Research of South Florida, Coral Gables

Miami Research Associates, Miami

AppleMed Research, Miami

Johnson County Clin-Trials, Lenexa

Tekton Research, Austin

Puerto Rico Clinical and Translational Research Consortium, San Juan

Ponce Medical School Foundation, Santurce